LEADS BIOLABS-B (09887) rose nearly 6% again. At the time of writing, the stock was up 4.63%, trading at HK$62.2, with a turnover of HK$11.4228 million. The company announced that LBL-034, its GPRC5D/CD3 bispecific antibody independently developed based on its proprietary TCE technology platform, LeadsBody, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM). This marks another significant milestone in the product's international development path, following the FDA's Orphan Drug designation granted in October 2024, signifying further international regulatory recognition of its clinical value and development strategy. It is reported that LBL-034 is a humanized bispecific T-cell engager targeting both GPRC5D and CD3.